Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page
- ChecktodayChange DetectedA MedlinePlus Genetics resource link for multiple myeloma is shown, and the site revision label changes from v3.8.0 to v3.8.1.SummaryDifference0.2%

- Check7 days agoChange DetectedThe study record’s related-resource links no longer include the MedlinePlus Genetics reference or the multiple-myeloma topic listing.SummaryDifference0.2%

- Check14 days agoChange DetectedThe NIH banner announcing updates and FAQs about the agency’s terminology transition was removed.SummaryDifference1%

- Check21 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedAn NIH-wide notice announces a transition in terminology, saying agencies are using “Super Intelligence” instead of “Artificial Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check35 days agoChange DetectedThe ClinicalTrials.gov error page’s footer revision identifier changed from v3.7.1 to v3.7.2. The study record still displays a 403 Forbidden message.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.